Evguenia Maiorova

Gilead Sciences (United States) — United States

Medicine · Health Sciences

5h-index126citations12works1.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(4), Hepatitis C virus research(4), Hepatitis B Virus Studies(4), Genomics and Phylogenetic Studies(2), COVID-19 Clinical Research Studies(2)

Publications12 total

Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys
Nature Communications·2025· 2 citedOpen Access
Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial
Clinical Infectious Diseases·2024Open Access
SAT-371 No amino acid substitution in HBV PreS1, HDAg, or NTCP associated with suboptimal response to bulevirtide in combination with pegylated interferon alfa-2a treatment in participants with chronic hepatitis delta: results from MYR204 a phase 2b study
Journal of Hepatology·2024
SAT-405 Differential expression and sequence variants of sodium taurocholate cotransporting polypeptide (NTCP) do not affect HDV inhibition by Bulevirtide (BLV)
Journal of Hepatology·2024
Recommendations for Uniform Variant Calling of SARS-CoV-2 Genome Sequence across Bioinformatic Workflows
Viruses·2024· 4 citedOpen Access
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV
JHEP Reports·2023· 8 citedOpen Access
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
Journal of Hepatology·2023· 22 cited
Towards increased accuracy and reproducibility in SARS-CoV-2 next generation sequence analysis for public health surveillance
2022· 6 citedOpen Access
Sequence characterization of extracellular <scp>HBV RNA</scp> in patient plasma
Journal of Viral Hepatitis·2022· 1 cited
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
Antimicrobial Agents and Chemotherapy·2022· 74 citedOpen Access
Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants
2022· 6 citedOpen Access
Characteristics of spontaneous revertants in haploid yeast
Yeast·1995· 3 cited

Frequent Co-authors

Hongmei Mo(9), Ross Martin(8), Savrina Manhas(7), Jiani Li(5), Thomas Aeschbacher(5), Roberto Mateo(5), Tomáš Cihlář(4), Jared Pitts(3), Jason K. Perry(3), Nicholas C. Riola(3), John P. Bilello(3), Yang Liu(3), Simin Xu(3), Silvia Chang(3), Ross Martin(3), Tahmineh Yazdi(3), Lindsey May(3), Tarik Asselah(3), Christopher J. Richards(3), Caleb Marceau(3)